Lumito notifies changes to terms for the issue of free-of-charge warrants
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumito signs an agreement with Uniogen Oy
Lumito AB and the Finnish company Uniogen Oy have signed a cooperation agreement for the production of Lumito’s immunohistochemical reagent kit, SCIZYS Erbium Kit. The reagent kit is part of Lumito’s product offering and is based on upconverted nanoparticles. Since June 2022, Lumito has had a Letter of Intent in place with Uniogen Oy (formerly […]
Successful results from a pre-study completed in collaboration with Umeå University, Sweden, shows that Lumito’s technique offers better possibilities compared with other immunohistochemical methods
A now completed pre-study, initiated at the beginning of this year in collaboration with a research group at Umeå University in Sweden led by Assistant Professor Daniel Öhlund has yielded successful results. The research group intended to identify how Lumito's UCNP (Up-Converting Nano Particles) technology could be used to improve the ability to visualise protein […]
Images of high and stable quality offer excellent assessment possibilities
Lumito’s objective is to create high-quality stainings of tissue sections and corresponding imaging. A key effort has been to achieve a repeatable and robust staining methodology that can generate imaging that is optimal for a digital, visual evaluation. These objectives have now been achieved, according to Dr. Bo Holmqvist. Bo Holmqvist (CSO, Imagene-iT AB) has […]
Correction of previously published press release concerning the early publication of the quarterly report
The press release published on 18 October at 13.00 contains incorrect information, as the Quarterly Report 3 2021 has not been audited. For further information, please contact: Lumito's CEO, Mattias Lundin e-mail: ml@lumito.se phone: 076-868 45 09 Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide […]
Earlier quarterly report in Lumito AB (publ)
Lumito AB (publ) hereby announces that the Board of Directors has decided to bring forward the company's report for quarter 3, 2021 to 20 October 2021, as the compilation work has progressed faster than expected and the auditors have reviewed the report. The Company's financial calendar has been updated and can be found here. For […]
Change of mentor to Mangold Fondkommission
Lumito AB has entered into an agreement with Mangold Fondkommission AB to act as the company's mentor in trading on NGM Nordic SME. Mangold Fondkommission will take over as mentor for the company on 15 October 2021. Lumito has simultaneously terminated the agreement with G&W Fondkommission AB, which expired on 14 October 2021. For further […]
Scanner with improved functionality installed
A life science consultant from TTP plc has delivered the next version of the Lumito’s scanner, with improved functionality, and assisted in the installation process. The new scanner entails, among other things, greater capacity to test new indications and to complete the evaluation of the breast cancer marker Her2. – Due to the pandemic, this was […]
Patent application approved in an additional country – Brazil
Lumito's (https://lumito.se/en/home/) basic patent, a patent in the first patent family protecting the use of upconverting nanoparticles (UCNPs) for imaging in scattering materials, such as human tissue, has now been approved in Brazil. Among other countries, the company is awaiting response to an application concerning India. – The approval of our basic patent is an important […]
Lumito develops the tissue diagnostics of the future – basic patent now granted in Europe
Lumito's product comprises an instrument and staining reagents based on UCNPs (up-converting nanoparticles). The instrument is intended for use in tissue diagnostics, to provide pathologists visual depictions of tissue samples as an input for making diagnosis. The technology is patented across three global patent families that cover the creation of high-quality imaging of tissue, for […]
